Cardiovascular Research Center, Icahn School of Medicine, Mount Sinai, NY.
Circulation. 2019 Jan 22;139(4):518-532. doi: 10.1161/CIRCULATIONAHA.118.033794.
Despite its functional importance in various fundamental bioprocesses, studies of N-methyladenosine (m6A) in the heart are lacking. Here, we show that the FTO (fat mass and obesity-associated protein), an m6A demethylase, plays a critical role in cardiac contractile function during homeostasis, remodeling, and regeneration.
We used clinical human samples, preclinical pig and mouse models, and primary cardiomyocyte cell cultures to study the functional role of m6A and FTO in the heart and in cardiomyocytes. We modulated expression of FTO by using adeno-associated virus serotype 9 (in vivo), adenovirus (both in vivo and in vitro), and small interfering RNAs (in vitro) to study its function in regulating cardiomyocyte m6A, calcium dynamics and contractility, and cardiac function postischemia. We performed methylated (m6A) RNA immunoprecipitation sequencing to map transcriptome-wide m6A, and methylated (m6A) RNA immunoprecipitation quantitative polymerase chain reaction assays to map and validate m6A in individual transcripts, in healthy and failing hearts, and in myocytes.
We discovered that FTO has decreased expression in failing mammalian hearts and hypoxic cardiomyocytes, thereby increasing m6A in RNA and decreasing cardiomyocyte contractile function. Improving expression of FTO in failing mouse hearts attenuated the ischemia-induced increase in m6A and decrease in cardiac contractile function. This is performed by the demethylation activity of FTO, which selectively demethylates cardiac contractile transcripts, thus preventing their degradation and improving their protein expression under ischemia. In addition, we demonstrate that FTO overexpression in mouse models of myocardial infarction decreased fibrosis and enhanced angiogenesis.
Collectively, our study demonstrates the functional importance of the FTO-dependent cardiac m6A methylome in cardiac contraction during heart failure and provides a novel mechanistic insight into the therapeutic mechanisms of FTO.
尽管 N6-甲基腺苷(m6A)在各种基础生物过程中具有重要的功能,但目前关于心脏中 m6A 的研究还很缺乏。在这里,我们展示了 FTO(肥胖相关蛋白)作为一种 m6A 去甲基化酶,在心脏的稳态、重塑和再生过程中对心肌收缩功能起着关键作用。
我们使用临床人体样本、猪和小鼠的临床前模型以及原代心肌细胞培养物来研究 m6A 和 FTO 在心脏和心肌细胞中的功能作用。我们通过使用腺相关病毒血清型 9(体内)、腺病毒(体内和体外)和小干扰 RNA(体外)来调节 FTO 的表达,研究其在调节心肌细胞 m6A、钙动力学和收缩性以及缺血后心脏功能中的作用。我们进行了 m6A RNA 免疫沉淀测序以绘制转录组范围内的 m6A,以及 m6A RNA 免疫沉淀定量聚合酶链反应测定以绘制和验证健康和衰竭心脏以及心肌细胞中 m6A 的单个转录本。
我们发现 FTO 在衰竭的哺乳动物心脏和缺氧心肌细胞中的表达减少,从而增加了 RNA 中的 m6A,并降低了心肌细胞的收缩功能。在衰竭的小鼠心脏中提高 FTO 的表达,可减轻缺血引起的 m6A 增加和心脏收缩功能下降。这是通过 FTO 的去甲基化活性来实现的,该活性选择性地去甲基化心脏收缩转录本,从而防止它们在缺血下降解并提高其蛋白表达。此外,我们证明在心肌梗死的小鼠模型中过表达 FTO 可减少纤维化并增强血管生成。
总的来说,我们的研究表明,FTO 依赖性心脏 m6A 甲基组在心力衰竭期间的心脏收缩中具有重要的功能意义,并为 FTO 的治疗机制提供了新的机制见解。